Loading
Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.
Nancy U. Lin is Director of the Metastatic Breast Cancer Program and Associate Chief of the Division of Breast Oncology at Dana-Farber Brigham Cancer Center. She is the leading authority on brain metastases from breast cancer, known for the HER2CLIMB analyses of tucatinib in patients with active brain disease and for defining the RANO-BM central nervous system response criteria used across trials. Her selected paper reports intracranial efficacy of tucatinib plus trastuzumab and capecitabine in previously treated HER2-positive breast cancer with brain metastases. She directs the metastatic breast cancer programme and continues work on CNS pharmacology in HER2-positive disease.
| Title | Journal | Year |
|---|---|---|
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial | Journal of Clinical Oncology | 2020 |
TMB-high is uncommon but not negligible in TNBC, rises at relapse, and the tumour-agnostic pembrolizumab indication makes it worth measuring on a metastatic biopsy.
PTEN loss, the most common PI3K-pathway lesion in TNBC, may mark primary immunotherapy resistance, and TMB may add to PD-L1 in choosing who gets checkpoint blockade.
The 13.3-month median is the pre-immunotherapy, pre-antibody-drug conjugate benchmark against which first-line trials now reporting medians near two years are measured; the brain metastasis rate is why trials that exclude active brain disease leave the question unanswered.
Shares Prevalence and mutational determinants of high tumor mutation burden in breast cancer, Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer, Breast Cancer Research Foundation, Dana-Farber Brigham Cancer Center.
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
Shares Breast Cancer Research Foundation, Dana-Farber Brigham Cancer Center.
Shares Prevalence and mutational determinants of high tumor mutation burden in breast cancer, Dana-Farber Brigham Cancer Center, HER2-positive breast cancer.
Shares Breast Cancer Research Foundation, HER2-positive breast cancer.
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.